DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Average Target Price from Analysts

Shares of DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) have been given an average rating of “Moderate Buy” by the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $12.3333.

A number of brokerages recently issued reports on DMAC. Weiss Ratings reissued a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research report on Wednesday, January 21st. Lake Street Capital reaffirmed a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several large investors have recently made changes to their positions in the stock. Cooperman Leon G raised its position in DiaMedica Therapeutics by 98.2% in the third quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after purchasing an additional 1,619,761 shares during the period. Corient IA LLC purchased a new position in shares of DiaMedica Therapeutics during the third quarter worth $910,000. Paragon Associates & Paragon Associates II Joint Venture grew its stake in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after buying an additional 225,000 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of DiaMedica Therapeutics in the second quarter valued at $29,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of DiaMedica Therapeutics in the 3rd quarter valued at $687,000. 10.12% of the stock is currently owned by institutional investors and hedge funds.

DiaMedica Therapeutics Stock Performance

Shares of DiaMedica Therapeutics stock opened at $6.48 on Friday. The firm has a market capitalization of $349.16 million, a price-to-earnings ratio of -9.26 and a beta of 1.16. DiaMedica Therapeutics has a fifty-two week low of $3.19 and a fifty-two week high of $10.42. The stock has a 50 day moving average of $7.76 and a 200 day moving average of $7.64.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its earnings results on Monday, March 30th. The company reported ($0.17) EPS for the quarter, meeting analysts’ consensus estimates of ($0.17). The business had revenue of ($0.03) million during the quarter, compared to analysts’ expectations of $13.50 million. Analysts forecast that DiaMedica Therapeutics will post -0.59 EPS for the current year.

Trending Headlines about DiaMedica Therapeutics

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its Q1 2026 EPS forecast to ($0.17) from ($0.18), signaling slightly smaller expected losses for the quarter. MarketBeat Report
• Positive Sentiment: Q2 2026 EPS estimate was lifted to ($0.18) from ($0.19), another incremental improvement to near‑term profitability expectations. MarketBeat Report
• Positive Sentiment: Q3 2026 EPS now projected at ($0.19), up from ($0.20), continuing the trend of reduced loss estimates across 2026 quarters. MarketBeat Report
• Positive Sentiment: Q4 2026 EPS was raised to ($0.21) from ($0.22), consistent with HC Wainwright nudging 2026 quarterly forecasts toward smaller losses. MarketBeat Report
• Positive Sentiment: HC Wainwright lifted FY2026 and FY2027 EPS estimates to ($0.75) from ($0.79), trimming expected full‑year losses and implying improving operating outlook vs. prior forecasts. MarketBeat Report
• Positive Sentiment: FY2028 EPS was nudged to ($0.35) from ($0.37), another minor upgrade in the multi‑year outlook. MarketBeat Report
• Positive Sentiment: HC Wainwright published a long‑range estimate projecting FY2030 EPS of $0.56, marking an expected transition to profitability in their model — a materially positive long‑term signal if the company hits the pathway to that outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS view to $0.14 from $0.15 — a small downgrade that partially offsets the otherwise uniform set of upgrades. MarketBeat Report

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.